Health & Fitness
Health and Fitness
Health and Fitness
Mon, February 18, 2013Sun, February 17, 2013Fri, February 15, 2013Thu, February 14, 2013Wed, February 13, 2013Tue, February 12, 2013Mon, February 11, 2013Sun, February 10, 2013Fri, February 8, 2013Thu, February 7, 2013Wed, February 6, 2013Tue, February 5, 2013Mon, February 4, 2013Sun, February 3, 2013Sat, February 2, 2013Fri, February 1, 2013Thu, January 31, 2013Wed, January 30, 2013Tue, January 29, 2013Rigel to Present at BIO CEO amp;; Investor Conference
Published in Health and Fitness on Thursday, February 7th 2013 at 4:46 GMT by Market Wire
Rigel to Present at BIO CEO & Investor Conference -- SOUTH SAN FRANCISCO, Calif., Feb. 7, 2013 /PRNewswire/ --
SOUTH SAN FRANCISCO, Calif., Feb. 7, 2013 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: [ RIGL ]) today announced that James M. Gower , the company's chairman and chief executive officer, is scheduled to present a company overview at the 15th Annual BIO CEO & Investor Conference in New York City on Monday, February 11th at 10:00 a.m. ET.
To access the live webcast of the presentation or the subsequent archived recording, log on to [ www.rigel.com ]. Please connect to Rigel's website several minutes prior to the start of the live webcast to ensure adequate time for any software download that may be necessary.
About Rigel ([ www.rigel.com ])
Rigel Pharmaceuticals, Inc. (Nasdaq: [ RIGL ]) is a clinical-stage drug development company that discovers and develops novel, small-molecule drugs for the treatment of inflammatory and autoimmune diseases, as well as muscle disorders. Rigel's pioneering research focuses on intracellular signaling pathways and related targets that are critical to disease mechanisms. Rigel's productivity has resulted in strategic collaborations with large pharmaceutical partners to develop and market its product candidates. Current product development programs include fostamatinib, an oral SYK inhibitor that is in Phase 3 clinical trials for rheumatoid arthritis with its partner AstraZeneca; R343, an inhaled SYK inhibitor for asthma and R333, a topical JAK/SYK inhibitor for discoid lupus – both of which have commenced Phase 2 clinical trials; and, R348, a topical JAK/SYK inhibitor in a Phase 1 clinical trial for the treatment of chronic dry eye.
Contact: Ryan Maynard
Phone: 650.624.1284
Email: [ invrel@rigel.com ]
SOURCE Rigel Pharmaceuticals, Inc.
RELATED LINKS
[ http://www.rigel.com ]
